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Abstract
BACKGROUND & AIMS—Campylobacter jejuni is the worldwide leading cause of bacterial-
induced enteritis. The molecular and cellular events that lead to campylobacteriosis are poorly
understood. We identify mammalian target of rapamycin (mTOR) as a signaling pathway that
leads to C jejuni-induced intestinal inflammation.
METHODS—Germ-free (control) or conventionally-derived interleukin (Il)10−/− mice that
express enhanced green fluorescent protein under the control of NF-κB (Il10 −/−; NF-κBEGFP
mice) were infected with C jejuni (109 CFU/mouse) for 12 days; their responses were determined
using histologic, semi-quantitative reverse transcription PCR, fluorescence in situ hybridization,
transmission electron microscopy, and tissue culture analyses. mTOR signaling was blocked by
daily intraperitoneal injections of the pharmacologic inhibitor rapamycin (1.5 mg/kg). CD4+ T
cells were depleted by intraperitoneal injections of antibodies against CD4 (0.5 mg/mouse, every 3
days). Bacterial survival in splenocytes was measured using a gentamycin killing assay.
RESULTS—C jejuni induced intestinal inflammation, which correlated with activation of mTOR
signaling and neutrophil infiltration. The inflamed intestines of these mice had increased levels of
Il-1β, Cxcl2, Il-17a, and EGFP; C jejuni localized to colons and extra-intestinal tissues of infected
Il10−/−; NF-κBEGFP mice, compared with controls. Rapamycin, administered before or after
introduction of C jejuni, blocked C jejuni-induced intestinal inflammation and bacterial
accumulation. LC3II processing and killing of C jejuni were increased in splenocytes incubated
with rapamycin, compared with controls.
CONCLUSIONS—mTOR signaling mediates C jejuni-induced colitis in Il10−/− mice,
independently of T-cell activation. Factors involved in mTOR signaling might be therapeutic
targets for campylobacteriosis.
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INTRODUCTION
Campylobacter jejuni is a gram-negative category B priority food- and water-borne
pathogen and the worldwide leading bacterial causative agent of enteritis.1 The Centers for
Disease Control and Prevention estimate that 2.4 million subjects are infected with C. jejuni
resulting in 124 deaths every year in the United States.2_ENREF_2_ENREF_2 Clinical
symptoms of C. jejuni infection include abdominal cramps, watery to bloody diarrhea, fever
and gastrointestinal inflammation.3 At the cellular level, C. jejuni infected patients display
infiltration of immune cells such as neutrophils, crypt abscesses and presence of fecal
leukocytes.4 Although the intestinal disease self-resolves within one week, a small portion
of patients (1:1000) develop extra-intestinal sequelae such as Guillain-Barre Syndrome
(GBS) and reactive arthritis.5 Interestingly, C. jejuni exposure is also responsible for
initiation and relapse of inflammatory bowel diseases (IBD)6 and post-infectious irritable
bowel syndrome7.
Despite the prevalence of C. jejuni induced illness and negative socio-economic impact, a
paucity of information is available regarding the molecular and cellular events involved in
campylobacteriosis. The major contributing factor to our poor understanding of
campylobacteriosis is the lack of robust experimental models mimicking the various phases
of acute human infection. Although some mammals including monkey,8 ferret9 and piglet10
have provided valuable information regarding cellular events associated with
campylobacteriosis, limited reagents and lack of genetic manipulation in these models have
constrained the generation of deep mechanistic understanding. We recently established an
acute model of campylobacteriosis using germ-free Il10−/− mice.11 In this model, C. jejuni
induces a rapid (5 days) and robust inflammatory (bloody diarrhea) response to the
microorganism. However, the cellular and molecular details responsible for this host
response remained undefined.
Mammalian target of rapamycin (mTOR) plays an important role in cell growth and
proliferation.12 The mTOR complex is composed of two entities: mTOR complex 1
(mTORC1) and mTOR complex 2 (mTORC2). mTORC1 is a downstream target of
phosphoinositide 3-kinases (PI3K) and is sensitive to the pharmacological inhibitor
rapamycin.13 The PI3K/mTOR pathway has long been implicated in regulating adaptive
immunity by targeting T cell proliferation and activation.14 Recent evidence implicates
PI3K/mTOR signaling as a key regulatory pathway of the innate immune host response. For
example, rapamycin suppresses GM-CSF or IL-8 induced human neutrophil migration in
vitro.15 In addition, PI3K signaling mediates IL-17 expression in inflamed murine lungs.16
Interestingly, IL-17 drives early neutrophil infiltration induced by i.p. Escherichia coli
infection in mice.17 Finally, mTOR signaling modulates autophagic responses involved in
bacterial killing and clearance.18
In this study, we hypothesized that mTOR represents an important signaling event regulating
host response to C. jejuni infection. Our findings demonstrated that mTOR signaling
regulates C. jejuni induced expression of inflammatory mediators, neutrophil infiltration and
bacterial clearance. These molecular and signaling events represent critical steps in C. jejuni
induced intestinal inflammation and could define potential new therapeutic targets.
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All animal protocols were approved by the Institutional Animal Care and Use Committee of
the University of North Carolina at Chapel Hill. Germ-free 8–12 week old Il10−/−; NF-
κBEGFP (129/SvEv; C57BL/6 mixed background) mice were transferred from germ-free
isolators and immediately gavaged with 109 C. jejuni cfu/mouse (strain 81–17619). Mice
were then housed under Specific Pathogen-Free (SPF) conditions and sacrificed at 4 or 12
days. Germ-free Il10−/−; NF-κBEGFP mice were also gavaged with 107 Salmonella
Typhimurium (S. Typhimurium strain CA32) cfu/mouse for 2 days or 107 Escherichia coli
(E. coli strain NC 101) cfu/mouse for 12 days. Conventionally-derived Il10−/−; NF-
κBEGFP mice were put on an antibiotic cocktail (streptomycin 2 g/L, gentamycin 0.5 g/L,
bacteriocin 1 g/L and ciprofloxacin 0.125 g/L) in water for 7 days and antibiotics were
withdrawn 24 hr prior infection. The mice were then gavaged with 109 C. jejuni cfu/mouse
for 14 days. To inhibit mTOR signaling, mice were injected daily i.p. with rapamycin (1.5
mg/kg) (Fisher Scientific). At the end of the experiment, mice were euthanized using CO2
intoxication. Colon, mesenteric lymph nodes (MLN) and spleen were collected for further
processing RNA, protein or C. jejuni culture on Campylobacter selective blood plates
(Remel) for 48 h at 37 °C using the GasPak system (BD). Colons were fixed in 10%
buffered formalin (Fisher Scientific) overnight, paraffin-embedded, sectioned, and stained
with H&E for histological evaluation. Images were acquired using a DP71 camera and DP
Controller 3.1.1.276 (Olympus). Intestinal inflammation was scored by evaluating the
degree of lamina propria immune cell infiltration, goblet cell depletion, architectural
distortion, as well as crypt hyperplasia, ulceration, and abscesses using a score from 0–4.11
Cecal and colonic inflammation induced by S. Typhimurium was evaluated using a score
from 0–13 as described.20
CD4+ cell depletion
C. jejuni infected mice were injected with anti-CD4 antibody (BioXcell) (i.p. 0.5 mg/mouse,
every 3 days) to deplete CD4+ cells. At the end of the experiment, mice were euthanized
using CO2 intoxication. Colons were resected and processed for H&E staining and colitis
evaluation. Spleen and MLN were collected and processed into single cell suspensions after
erythrocyte lysis.
Western blotting
Whole tissues were lysed in Laemmli buffer and 20 μg of protein was separated by SDS-
PAGE, transferred to nitrocellulose membranes and protein detected using enhanced
chemiluminescence reaction (ECL) as described previously.11 Primary antibodies used were
phospho-p70S6K (T389) and p70S6K (Cell Signaling), EGFP (Sigma), LC3 I/II (MBL) and
Actin (BP Biomedicals).
Enhanced GFP (EGFP) macro- and micro-imaging
Il10−/−; NF-κBEGFP mice were sacrificed; the colon was dissected and immediately imaged
using a charge-coupled device camera in a light-tight imaging box with a dual-filtered light
source and emission filters specific for EGFP (LT-99D2 Illumatools; Lightools Research).
For microimaging, colonic segments were cut open and fixed in 4% paraformaldehyde
overnight at 4°C, and then permeabilized in 2% triton overnight at 4°C. The tissues were
then immersed in FocusClear (CelExplorer labs) and then stained with DAPI. The tissues
were put on slides with lumen side facing the lens. NF-κB derived EGPF were examined
using Olympus FV1000 confocal multiphoton upright microscope system with Olympus
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Fluoview 2.0 software. Acquired images were reconstructed into 3-D using Imaris
(Bitplane).
Fluorescence in situ hybridization (FISH)
Cy3-tagged 5'AGCTAACCACACCTTATACCG3'21 was used to probe the presence of C.
jejuni. Deparaffinized, formalin-fixed 5 μm thick sections were incubated for 15 minutes in
lysozyme (300,000 Units/ml lysozyme; Sigma-Aldrich) buffer (25 mM Tris pH 7.5, 10 mM
EDTA, 585 mM sucrose, and 0.3 mg/ml sodium taurocholate) at room temperature and
hybridized overnight at 46 °C in hybridization chambers with the oligonucleotide probe
(final concentration of 5 ng/μl in a solution of 30 percent formamide, 0.9 M sodium
chloride, 20 mM Tris pH 7.5, and 0.01% sodium dodecyl sulfate). Tissue sections were
washed for 20 minutes at 48 °C in washing buffer (0.9 M sodium chloride, 20 mM Tris pH
7.5) and once in distilled water for 10 seconds, dried at 46 °C, mounted with DAPI mount
media, and imaged using a Zeiss LSM710 Spectral Confocal Laser Scanning Microscope
system with ZEN 2008 software. Acquired images were analyzed using BioimageXD.22 For
whole tissue FISH, colons were fixed in 4% paraformaldehyde overnight at 4°C, 2% triton
overnight at 4°C, and C. jejuni probe was added and incubated overnight at 46°C. The whole
tissue was immersed in FocusClear, imaged on an Olympus FV1000 microscope and
reconstructed into 3-D using Imaris.
Immunohistochemistry (IHC)
Deparaffinized colon sections were treated with 3% H2O2 for 10 minutes to quench
endogenous peroxidases. Antigen retrieval was performed using microwave heating for 10
min in 10 mM citrate buffer pH 6.0. Sections were blocked in 5% goat serum TBS-T for 1
hour. The slides were incubated overnight at 4°C with an anti-MPO antibody (1:400)
(Thermo Scientific). Secondary biotinylated antibody was diluted at 1:1000 with the
Vectastain ABC Elite Kit (Vector Laboratories). Visualization was performed using DAB
chromogen (DAKO). Finally, sections were counterstained with hematoxylin for 5 seconds.
Sections were imaged at the Olympus microscope using DP 71 camera and DP Controller
3.1.1.276 (Olympus).
Statistical analysis
Values are shown as mean ± SEM as indicated. Differences between groups were evaluated
with the nonparametric Mann-Whitney U test. Experiments were considered statistically
significant if P values < 0.05. All calculations were performed using Prim 5.0 software.
RESULTS
mTOR mediates C. jejuni-induced colitis
Although the role of mTOR has moved beyond that of a modulator of T cell function, the
involvement of this multifunctional kinase in host responses to pathogenic bacteria has not
been clearly explored. To investigate the impact of mTOR on C. jejuni-induced colitis in
vivo, germ-free Il10−/−; NF-κBEGFP mice were transferred to specific pathogen free (SPF)
housing and immediately gavaged with C. jejuni (109 CFU/mouse) and then injected i.p.
daily with either vehicle (5% DMSO PBS) or rapamycin (1.5 mg/kg body weight) for 12
days. Western blot analysis showed that rapamycin attenuated C. jejuni induced
phosphorylation of p70S6 kinase (T389), a downstream target of mTOR (Fig. 1A). As
previously reported,11Il10−/−; NF-κBEGFP mice infected with C. jejuni showed severe
intestinal inflammation as seen by extensive immune cell infiltration, epithelial ulceration,
goblet cell depletion and crypt hyperplasia and abscesses compared to uninfected mice (Fig.
1B and 1D). Interestingly, rapamycin blocked C. jejuni-induced intestinal inflammation in
Sun et al. Page 4













Il10−/−; NF-κBEGFP mice. Since germ free mice have an immature immune system, we next
treated conventionally-derived Il10−/−; NF-κBEGFP mice with antibiotics and then infected
these mice with C. jejuni for 12 days. As observed in germ free mice, C. jejuni induced
severe intestinal inflammation in conventionally-derived Il10−/−; NF-κBEGFP mice, an effect
significantly attenuated by rapamycin exposure (Supplemental Fig. S1a–b).
To determine the specificity of rapamycin on other colitogenic microorganisms, we infected
germ free Il10−/−; NF-κBEGFP mice with the enteric pathogens Salmonella Typhimurium
(107 CFU/mouse) for 2 days or Escherichia coli NC 101 (107 CFU/mouse) for 12 days.
Interestingly, E. coli infected Il10−/−; NF-κBEGFP mice did not develop intestinal
inflammation at this time point, suggesting a specific host response to C.jejuni infection
(Supplemental Fig. S2a–b). However, Il10−/−; NF-κBEGFP mice infected with S.
Typhimurium developed severe cecal and colonic inflammation, which was strongly
attenuated by rapamycin exposure (Supplemental Fig. S3). These results suggest that mTOR
signaling mediates deleterious responses from different enteropathogenic microorganisms.
C. jejuni induced intestinal inflammation is evident as early as day 4 in Il10−/−; NF-κBEGFP
infected mice (Supplemental Fig. S4a–b).11 To further test if rapamycin may be used as an
intervention agent, we injected the inhibitor daily to C. jejuni infected (4 days) Il10−/−; NF-
κBEGFP mice and collected intestinal tissues at 12 days. Remarkably, rapamycin treatment
strongly reversed C. jejuni induced intestinal inflammation and bloody diarrhea (Fig. 1C and
1E, Supplemental Fig. S5a–b).
Since rapamycin has immunomodulatory effects on T cells, we depleted CD4+ T cells using
an anti-CD4 antibody (0.5 mg/mouse/every three days) to address the function of these cells
in the acute phase of campylobacteriosis. Notably, C. jejuni induced colitis was only slightly
inhibited (~20%) in CD4+ T cell-depleted mice compared to control (Fig. 2A–B). Complete
depletion of CD4 cells was observed in the spleen and MLN cellular compartment of
antibody-treated mice (Fig. 2C–D). These results suggest that the early phase of C. jejuni-
induced colitis is mostly mediated by an innate immune response and that rapamycin likely
targets activities of innate immune cells.
mTOR regulates C. jejuni induced NF-κB activity and proinflammatory gene expression
We previously showed that NF-κB is activated in C. jejuni infected Il10−/−; NF-κBEGFP
mice.11 To evaluate the impact of mTOR signaling on NF-ĸB activity, EGFP expression in
the colon of Il10−/−; NF-κBEGFP mice was visualized using a CCD camera macroimaging
system. Il10−/−; NF-κBEGFP mice infected with C. jejuni displayed enhanced colonic NF-
κBEGFP expression with strongly positive lymphoid aggregates (arrow heads) compared to
uninfected mice (Fig. 3A). Interestingly, the colon of rapamycin-treated, C. jejuni-infected
Il10−/−; NF-κBEGFP mice displayed reduced EGFP expression compared to untreated,
infected-mice. Consistent with these findings, western blot analysis of colonic lysates
demonstrated reduced EGFP expression in rapamycin-treated, C. jejuni-infected mice (Fig.
3B).
To further evaluate the distribution of NF-κBEGFP positive cells within the colon, whole
colonic tissue was visualized using confocal microscopy coupled with 3-D image
reconstruction. In accordance with the macroimaging and Western blot data, C. jejuni-
infected Il10−/−; NF-κBEGFP mice showed numerous EGFP positive cells in the colonic
lamina propria compared to uninfected mice (Fig. 3C and supplementary Fig3video1.mov,
Fig3video2.mov, Fig3video3.mov and Fig3video4.mov). Strikingly, colonic EGFP tissue
expression was strongly reduced in rapamycin-treated, C. jejuni-infected Il10−/−; NF-
κBEGFP mice compared to untreated mice.
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We next examined the impact of rapamycin on expression of various NF-κB dependent
proinflammatory mediators involved in bacterial host responses. C. jejuni infection strongly
induced I1-1β, Cxcl2 and Il-17a mRNA accumulation in colonic tissue of Il10−/−; NF-
κBEGFP mice, effects attenuated by 79, 75, and 92%, respectively in rapamycin-treated, C.
jejuni-infected mice (Fig. 4A). Consistent with these findings, secreted IL-1β and IL-17
from supernatant of cultured colon explants was reduced by 59% and 94% respectively
while production of these cytokines was attenuated by 41% and 82% in MLN of rapamycin-
treated, C. jejuni-infected mice compared to control mice (Fig. 4B). Interestingly, C. jejuni-
induced colonic Il-12p40 and Tnfα mRNA accumulation were not significantly inhibited by
rapamycin treatment, suggesting that inflammatory mediators are selectively affected by
mTOR signaling (Supplemental Fig. S6).
Neutrophils participate in C. jejuni-induced colitis
Neutrophil infiltration is a hallmark of acute infection and represents an important feature of
human campylobacteriosis.4 Of note, rapamycin strongly reduced C. jejuni induced
expression of the neutrophil marker myeloperoxidase (MPO) in colonic tissue of infected
Il10−/−; NF-κBEGFP mice (Fig. 5A). Moreover, the ratio of Gr-1+:CD45+ cells significantly
decreased (41%) in the blood of rapacymin-treated, C. jejuni infected mice compared to
untreated, infected mice (Fig. 5B). Finally, transmission electron microscope (TEM)
analysis showed neutrophil accumulation in colonic crypt, which associates with microvilli/
glycocalyx destruction (Fig. 5C). Notably, these pathological features were not observed in
rapamycin-treated mice (Fig. 5C, right panel).
mTOR mediates C. jejuni invasion
We next investigated the impact of mTOR signaling on intestinal and extra-intestinal C.
jejuni tissue distribution. Following infection and treatment with rapamycin, C. jejuni DNA
was visualized in the colon of Il10−/−; NF-κBEGFP mice using fluorescence in situ
hybridization (FISH) and confocal microscopy imaging. Interestingly, while C. jejuni was
detected deeply in the inflamed crypts and in the lamina propria section of the intestine of
untreated mice, C. jejuni DNA was barely detectable in rapamycin-treated mice (Fig. 6A).
To gain a better perspective of C. jejuni invasion, FISH was performed using fresh-fixed
colonic tissues sections, and then imaged with confocal microscopy coupled with 3-D
visualization. Interestingly, while C. jejuni extensively invaded the colon of untreated mice,
its presence is strongly reduced in rapamycin-treated mice (Fig. 6B and supplementary
Fig6video1.mov and Fig6video2.mov). To further characterize C. jejuni invasion, colonic
tissue was also imaged using TEM. The presence of spirally shaped C. jejuni (arrow)
lacking its outer membrane was detected in epithelial cells (Fig. 6C left panel). Also the
absence of a vesicular membrane around the invading bacteria suggests that phagosome
formation in epithelial cells is not a host response to the bacterium. Consistent with FISH
results, intracellular C. jejuni were virtually absent and microvilli were intact in epithelial
cells of rapamycin-treated mice (Fig. 6C right panel).
Reduced C. jejuni in the colon of rapamycin-treated mice suggests that the bacteria were
eliminated or were able to evade/translocate to extra-intestinal tissues. To resolve this issue,
we aseptically collected samples from the stool, colon, spleen and MLN and enumerated C.
jejuni on Remel Campylobacter selective plates. Consistent with the FISH and TEM results,
rapamycin treatment reduced C. jejuni colonic tissue invasion by 90% compared to C.
jejuni-infected, untreated mice (Fig. 6D). Furthermore, rapamycin treatment strongly
reduced C. jejuni presence in the MLN and spleen of infected mice compared to untreated,
infected mice. Altogether, these findings identified mTOR signaling and neutrophil
infiltration as important events leading to C. jejuni invasion and pathogenesis.
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The above findings suggest that rapamycin favors bacterial clearance, which lead to
decreased innate response and intestinal inflammation. To directly test the impact of
rapamycin on bacterial survival, we infected splenocytes isolated from Il10−/− mice with C.
jejuni and performed a gentamycin killing assay. Interestingly, rapamycin enhanced C.
jejuni killing in splenocytes at 4hr compared to untreated cell (Fig. 7A). Western blot
analysis showed that rapamycin attenuated C. jejuni induced phosphorylation of p70S6
kinase (T389) and enhanced LC3 II conversion, a marker of autophagy (Fig.7B).
Interestingly, C. jejuni exposed to rapamycin as high as 1 mM did not alter the growth/
viability of the bacterium. Altogether, these findings showed that increased mTOR signaling
following C. jejuni infection mediates proinflammatory response, likely by preventing host-
mediated bacterial killing.
DISCUSSION
The fundamental molecular host response to C. jejuni infection remains virtually unknown.
In this study, we present clear evidences that C. jejuni –mediated intestinal inflammation is
caused by activation of the host mTOR signaling pathway and neutrophil infiltration.
Comparable intestinal inflammation between CD4+ cells depleted and untreated mice
indicates that C. jejuni induced colitis is mostly driven by innate immune cells at day 12.
Although CD4+ T cells are not involved in the development of intestinal inflammation by
day 12, adaptive host response is an important hallmark of campylobacteriosis.23
Interestingly and in contrast to C. jejuni, the adherent invasive E. coli NC101 failed to
induce colitis after 12 days, whereas severe colitis developed after 10–20 weeks of
colonization with the same bacterium.24 In addition, colitis was observed as early as two
days in S. Typhimurium infected Il10−/− mice. These findings suggest a differential ability
of bacteria to trigger intestinal inflammation in Il10−/− mice. Using this robust and tractable
animal model, we demonstrate that C. jejuni induced mTOR signaling leads to increased
NF-κB activity and induction of NF-κB-dependent genes (cytokines/chemokines). FISH
assay and electron microscopy analysis showed that C. jejuni rapidly invades the intestinal
mucosal layer and triggers a host response involving neutrophil recruitment and formation
of crypt ulcers. Disruption of the crypt architecture by massive neutrophil influx likely
compromises the intestinal barrier integrity, which further favors bacterial uptake/invasion
and dissemination to extra-intestinal tissues as seen by enhanced bacterial counts in the
spleen and MLN. mTOR blockade with a pharmacological inhibitor strongly attenuated
campylobacteriosis in Il10−/− mice. Moreover, rapamycin was able to treat established C.
jejuni-induced intestinal inflammation.
A close examination of human campylobacteriosis suggests a preponderant role of
neutrophils in the course of the pathology. Histological assessment showed the presence of
numerous crypt abscesses and neutrophil infiltration in the intestinal mucosa of infected
patients.4 However, up until now the functional importance of neutrophil infiltration in C.
jejuni-induced pathogenesis has not been investigated. Although the main biological
function of neutrophils is to ingest and eliminate invading microorganisms, excessive
infiltration of these innate immune cells and release of various degradative enzymes and
oxidative products cause extensive collateral tissue damage to the host. For example,
neutrophil accumulation causes elevated IL-1β and CXCL2 production and subsequent joint
inflammation, an effect attenuated with anti-IL1β antibody treatment.25 Interestingly, TEM
showed that the microvilli and associated glycocalyx of epithelial cells in neutrophil-
infiltrated crypts are virtually ablated in C. jejuni-infected mice.–The molecular events
leading to neutrophil infiltration in the intestine of C. jejuni-infected mice is not entirely
clear. Induction of Il-17a and Cxcl2 genes is important for neutrophil expansion and
recruitment.26, 27 Interestingly, blocking mTOR with rapamycin decreased colonic Il-17a
and Cxcl2 expression, which correlated with reduction of neutrophils infiltration and crypt
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abscesses and with disease improvement. Although IL-17 is a signature cytokine of the
Th17 cells, our CD4 depletion experiment suggests that adaptive CD4+ T cells play a minor
role in campylobacteriosis. IL-17 is produced by a wide array of innate immune cells
including γδT cells, natural killer γδT cells and lymphoid tissue inducer cells.28 Since γδT
cells are highly abundant in the intestinal mucosa, it is tempting to speculate that these cells
are the source of IL-17 in our model. Interestingly, in an E. coli infectious model, neutrophil
recruitment to the peritoneal cavity is dependent on innate γδT cell-mediated IL-17
secretion.17 Similarly, Klebsiella pneumonia-induced lung inflammation is attenuated in
Il-17r−/− mice, which correlated with neutrophil recruitment and G-SCF and CXCL2
expression.27 Further studies would be needed to define the role of IL-17 in
campylobacteriosis.
Another important function of mTOR signaling is the regulation of autophagy. Our findings
indicate that C. jejuni infiltration in the colon, MLN and spleen is dramatically reduced in
rapamycin-treated mice, suggesting increased bacterial killing. Using primary splenocytes,
we found that rapamycin enhanced C. jejuni killing, which correlated with enhanced LC3II
conversion. These findings suggest that C. jejuni induces mTOR signaling as a mean to
avoid host-mediated killing, possibly by prevent adequate autophagy response. Further
studies would be needed to definitively establish the role of autophagy in
campylobacteriosis. Interestingly, S. Typhimurium induced colitis was also inhibited by
rapamycin exposure, suggesting that mTOR may be the target of other enteropathogenic
microorganisms. mTOR has also been recently identified as a negative regulator of LPS-
induced NF-κB signaling in monocytes, macrophage, and primary DC.29 Therefore,
blocking mTOR signaling could enhance NF-κB signaling and production of inflammatory
mediators involved in bacterial killing. However, our data do not support this hypothesis as
EGFP expression (NF-κB activity) and some NF-κB-dependent inflammatory mediators are
reduced in rapamycin-treated mice. While we observed decreased activation of NF-κB
(EGFP expression) and inflammatory gene expression in rapamycin-treated mice, these
observations are likely a secondary effect of the drug since direct NF-κB inhibitors failed to
prevent campylobacteriosis.11
Although the majority of C. jejuni infected patients recover within 2 to 10 days without any
specific treatment, a significant proportion develop severe clinical symptoms (fever, bloody
diarrhea and abdominal cramps) which requires antibiotic treatment to shorten symptom
durance.1 Recently, there are increasing concerns over C. jejuni resistance to antibiotics30
and post-infectious sequelae such as GBS, IBD and IBS.5–7 Immune based prevention or
intervention has attracted much attention as an alternative to antibiotic treatment.31 Based on
our novel findings, specific mTOR inhibitors (such as Rapamune, Torisel, Afinitor and
Zortress) already approved for human use could represent a potential alternative to
antibiotic-based therapy to treat campylobacteriosis. Further work would be needed before
mTOR is validated as a therapeutic target for campylobacteriosis.
In summary, this report defines the critical role of mTOR in mediating the pro-inflammatory
effect of C. jejuni infection. We report that neutrophil infiltration plays an active role in
pathogenesis of C. jejuni infection and modulation of the cellular/molecular events leading
to this process could represent a new therapeutic arsenal to control campylobacteriosis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Rapamycin prevents and treats C. jejuni induced colitis in Il10−/−; NF-κBEGFP mice
Cohorts of 5–14 germ-free Il10−/−; NF-κBEGFP mice were transferred to SPF conditions and
immediately gavaged with 109 C. jejuni/mouse and then injected i.p. with vehicle control
(Ctl, 5% DMSO), rapamycin (Rapa, 1.5 mg/kg body weight) for 12 days. For rapamycin
treatment (Rapa trt), C. jejuni-infected mice (4 days) were injected i.p. with rapamycin to
day 12. Colon was resected, fixed in formaldehyde and sections were stained with H&E or
protein extracts for Western blot analysis. (A) Western blot for total and phosphorylated
colonic p70S6. (B) Histological intestinal damage scores of rapamycin prevention on C.
jejuni infection. (C) Histological intestinal damage score of rapamycin treatment. (D) H&E
representation of the different experimental groups with crypt abscesses (arrow heads). (E)
H&E sections of rapamycin treatment mice. All graphs depict mean ± SE. **, P < 0.01, ***,
P < 0.001. Scale bar is 200 μm. Results are representative of 4 independent experiments.
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Figure 2. C. jejuni induced intestinal inflammation is independent of CD4 T cells activation
Three cohorts of 4–5 germ-free Il10−/−; NF-κBEGFP mice were transferred to SPF
conditions and immediately gavaged with 109 C. jejuni/mouse and then injected i.p. with
vehicle control (Ctl, PBS) or anti-CD4 antibody (anti-CD4, 0.5 mg/mouse/every 3 days).
(A) H&E representation of the different experimental groups. (B) Histological score of
intestinal inflammation. (C) Representative flow cytometry analysis of CD4+ cell population
change in the spleen. (D) Percentage flow cytometry results of CD4+ cell in the spleen and
MLN. All graphs depict mean ± SE. ***, P < 0.001. Scale bar is 200 μm. Results are
representative of 3 independent experiments.
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Figure 3. Rapamycin treatment reduces C. jejuni induced colonic EGFP expression in Il10 −/−;
NF-κBEGFP mice
Four cohorts of 5–14 germ-free Il10−/−; NF-κBEGFP mice were transferred to SPF
conditions and infected with C. jejuni/mice as described in Fig.1. Mice were injected i.p.
with vehicle (5% DMSO) or rapamycin (1.5 mg/kg body weight) for 12 days. (A) EGFP
expression in the mouse colon was visualized using a CCD camera macroimaging system.
(B) EGFP levels were analyzed by Western blot and (C) confocal microscopy visualization
of EGFP positive cells images in 3-D using Imaris. Results are representative of 3
independent experiments.
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Figure 4. Rapamycin attenuates C. jejuni induced expression of proinflammatory mediators
Four cohorts of 5–14 germ-free Il10−/−; NF-κBEGFP mice were treated as indicated in Fig.1.
Colons were resected and RNA extracted using Trizol. (A) Il1β, Cxcl2 and Il-17a mRNA
accumulation was quantified using an ABI 7900HT Fast Real-Time PCR System and
specific primers and data were normalized to Gapdh. (B) Colonic tissues and mesenteric
lymph nodes were cultured in RPMI 1640 medium supplemented with 3% FBS and 1%
antibiotics for 18 hrs. Supernatants were collected and IL-1β and IL-17 secretion measured
by ELISA. Data represent means ± SE *, P < 0.05 **, P < 0.01. Results are representative of
3 independent experiments.
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Figure 5. Neutrophils participate in C. jejuni induced colitis
Cohorts of 5–7 germ-free Il10−/−; NF-κBEGFP mice were transferred to SPF conditions and
infected/treated as indicated in Fig.1. (A) IHC representation of MPO positive colonic cells
(brown dots) in Control (Ctl), C. jejuni infected, rapamycin (Rapa) treated mice. Lower
panels (scale bar 20 μm) are magnified images of area shown in the upper panels (scale bar
200 μm). (B) Flow cytometry analysis for CD45+ and Gr-1+ cells in the peripheral blood of
infected and rapamycin-treated mice. (C) TEM images of colonic tissues from C. jejuni
infected with/without rapamycin treatment. Left panel shows accumulated neutrophils
(arrow heads) in a crypt with microvilli erosion (arrows). Right panel shows absence of
neutrophils with intact microvilli (arrows). Inserts in the lower right corners are magnified
images of framed area. Scale bar is 2 μm. Data represent means ± SE **, P < 0.01. Results
are representative of 3 independent experiments.
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Figure 6. mTOR signaling promotes C. jejuni invasion of the colon, MLN and spleen
Cohorts of 3–4 germ-free Il10−/−; NF-κBEGFP mice were transferred to SPF conditions and
infected/treated as indicated in Fig.1. (A) Clustered C. jejuni (red dots) in colonic section of
infected mice was detected using FISH. Inserts in the lower left corners are magnified
images of framed area. Scale bar is 100 μm. (B) Presence of clustered C. jejuni (red dots) in
whole colon tissue was determined using FISH and 3D-imaging. (C) Evidence of
intracellular (arrows, left panel) and luminal (right panel) C. jejuni in colonic tissues of
untreated or rapamycin-treated mice respectively. Lower panels (scale bar 200 nm) were
magnified images of area shown in the upper panels (scale bar 2 μm). (D) C. jejuni bacterial
count in the stool, colon, MLN and spleen of untreated or rapamycin-treated mice. Data
represent means ± SE *, P < 0.05. Results are representative of 3 independent experiments.
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Figure 7. Rapamycin promotes C. jejuni eradication and LC3II generation in splenocytes
Splenocyte was isolated from Il10−/− mice and infected with C. jejuni (MOI 50) and
cultured with rapamycin (100 nM). A gentamycin killing assay at 0 and 4 hr and WB assay
at 0.5, 1.5 and 4 hr were performed. (A) Percentage of C. jejuni survival in splenocytes. (B)
Western blot of colonic LC3 I/II and phosphorylated p70S6 in infected splenocytes.
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